GlassScriptPhysician profile
Carla A Spades
NPI 1265810907
$1,750.43
in general payments reported to CMS, 2019-2025
27 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $154 · 2021: $324 · 2022: $191 · 2023: $217 · 2024: $128 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.14 | 2019-2022 | |
| Dysis Medical, INC. | $141.72 | 2021-2023 | Dysis View, Dysis V3 Digital Coploscope, Dysis Ultra 2.0 |
| Avion Pharmaceuticals | $125.04 | 2019-2022 | |
| Sage Therapeutics, LLC | $121.32 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $95.75 | 2023-2025 | Slynd |
| Hologic Sales and Service, LLC | $95.24 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Allergan, INC. | $88.56 | 2019 | |
| Therapeuticsmd, INC. | $78.07 | 2019-2021 | |
| Astellas Pharma US INC | $69.82 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $56.88 | 2020 | |
| Sumitomo Pharma America, INC. | $55.67 | 2025 | Myfembree |
| Lupin INC. | $54.79 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $45.45 | 2025 | Qelbree |
| Coopersurgical, INC. | $44.66 | 2019-2024 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $40.86 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $39.52 | 2025 | Intrarosa, Femlyv |
| Medicem INC. | $36.01 | 2020-2021 | |
| Baxter Healthcare | $35.74 | 2022 | |
| Becton, Dickinson and Company | $34.40 | 2022-2023 | Bd Onclarity |
| Mayne Pharma Commercial LLC | $32.08 | 2021 | |
| Minerva Surgical, INC | $30.35 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.80 | 2019 | |
| Organon LLC | $24.65 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $22.28 | 2023 | Vivjoa |
| Genzyme Corporation | $17.62 | 2022 | |
| Pfizer INC. | $13.11 | 2019 | |
| Evofem Biosciences, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Spades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.